ARROWHEAD PHARMACEUTICALS, INC. (ARWR): Results of Operations and Financial Condition
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 arwr-202608048kex991.htm EX-99.1 Document EXHIBIT 99.1 PRESS RELEASE August 4, 2026 Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results Conference Call and Webcast Today, August 4, 2026 at 4:30 p.m. ET PASADENA, Calif., August 4, 2026 — Arrowhead Pharmac
How this was made
The 30-second read
Why it matters
Traders can update probabilities for plozasiran’s severe hypertriglyceridemia label expansion based on SHASTA-3/4 topline results and the company’s stated intent to use an FDA priority review voucher for an sNDA submission before end-2026. Commercial momentum for REDEMPLO and new ex-US authorizations add additional near-term sentiment support.
Market read
Material, company-specific catalysts across clinical efficacy, regulatory acceleration, and commercialization, released via an 8-K with an investor call scheduled the same day.
What to watch
The article provides limited detail on revenue trajectory drivers beyond prescription volume and does not quantify guidance or full financial outlook in the excerpt, which could temper the stock reaction.
Background
This is an SEC Form 8-K (Item 2.02) with an attached press release covering Arrowhead’s fiscal 2026 third-quarter results and multiple clinical, regulatory, and commercial updates.
Ticker impact
Arrowhead reported fiscal Q3 results and disclosed SHASTA-3/4 topline success for plozasiran, plus a newly acquired FDA priority review voucher tied to an sNDA before end-2026.
Near-term upside bias as traders price in accelerated FDA review timing and stronger efficacy/safety signals; volatility likely around the upcoming ESC Aug 30 late-breaker and sNDA timing.
The filing is a primary disclosure (8-K with results and press release) and includes multiple concrete catalysts: SHASTA-3/4 primary endpoint met, large median TG reductions, acute pancreatitis event reduction, and a PRV acquisition intended for an sNDA submission before end-2026.
Market effects
Reinforces momentum for RNAi therapeutics in cardiometabolic indications, potentially improving sentiment toward the broader RNAi/rare-disease biotech complex.
European Commission and Australia approvals for REDEMPLO expand ex-US commercialization credibility, supporting cross-region sales expectations.
ESC Aug 30 late-breaker and multi-geography regulatory plans can influence global risk appetite for lipid-disorder therapies.
Counterpoint
Despite strong topline efficacy, regulatory outcomes and commercial uptake remain uncertain, and the PRV does not guarantee approval or label expansion.
Key entities
- issuerArrowhead Pharmaceuticals, Inc.
NASDAQ-listed RNAi therapeutics company reporting fiscal 2026 Q3 results and disclosing plozasiran Phase 3 topline outcomes, PRV acquisition, and REDEMPLO commercialization/regulatory milestones.
- product_candidatePlozasiran
Arrowhead’s RNAi therapeutic for severe hypertriglyceridemia; SHASTA-3 and SHASTA-4 met primary and secondary endpoints per the filing.
- productREDEMPLO
Commercial RNAi medicine for familial chylomicronemia syndrome; the company reports prescription volume growth and new EC and TGA marketing authorizations.
- counterpartyMadrigal Pharmaceuticals
Partner in an exclusive worldwide license agreement for ARO-PNPLA3, including a $25 million upfront payment and potential milestones/royalties.
